Trials that use: Fisher exact test
New to this method? Read the tutorial →
4,441 results
- Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02698891).
- AwareIndependent statistical analysis of HIV Rapid Testing & Counseling in Sexually Transmitted Disease (STD) Clinics in the U.S.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- AXEBEAMIndependent statistical analysis of Neoadjuvant Bevacizumab, Capecitabine and Radiation Therapy With or Without Oxaliplatin Locally Advanced Rectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Azacitidine and CAPOX in Metastatic Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Azacitidine and CAPOX in Metastatic Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01193517).
- Azacitidine and Cisplatin for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Complete Statistical AnalysisIndependent statistical analysis of Azacitidine and Cisplatin for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- AZI001Independent statistical analysis of Azithromycin in Bronchiolitis Obliterans Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01009619).
- B-cell Immunity to Influenza (SLVP017)- Year 5, 2013: Complete Statistical AnalysisIndependent statistical analysis of B-cell Immunity to Influenza (SLVP017)- Year 5, 2013: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03020537).
- BAIndependent statistical analysis of Relative Bioavailability of Linaprazan for the Test Formulation vs. Reference Formulation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Bacterial Pneumonia Score (BPS) Guided Antibiotic Use in Children With Pneumonia and Pneumococcal Vaccine: Complete Statistical AnalysisIndependent statistical analysis of Bacterial Pneumonia Score (BPS) Guided Antibiotic Use in Children With Pneumonia and Pneumococcal Vaccine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Bacterial Resistance in Patients Receiving Post-Intravitreal Injection Antibiotics: Complete Statistical AnalysisIndependent statistical analysis of Bacterial Resistance in Patients Receiving Post-Intravitreal Injection Antibiotics: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02223338).
- BALLAD+Independent statistical analysis of A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid: primary endpoint results, effect estimate with…
- Barbed Suture Versus Non-Barbed Suture for Posterior Colporrhaphy: Complete Statistical AnalysisIndependent statistical analysis of Barbed Suture Versus Non-Barbed Suture for Posterior Colporrhaphy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04658784).
- Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus: Complete Statistical AnalysisIndependent statistical analysis of Baricitinib (LY3009104) in the Treatment of Cutaneous Lichen Planus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05188521).
- Barre Exercise in Parkinson’s: Complete Statistical AnalysisIndependent statistical analysis of Barre Exercise in Parkinson's: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06203990).
- Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations: Complete Statistical AnalysisIndependent statistical analysis of Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC: Complete Statistical AnalysisIndependent statistical analysis of BATTLE Program: Erlotinib in Previously Treated Subjects With Advanced NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00410059).
- BAY 0 9867 Cipro Pediatric Use Study (QUIP): Complete Statistical AnalysisIndependent statistical analysis of BAY 0 9867 Cipro Pediatric Use Study (QUIP): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00761462).
- BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer: Complete Statistical AnalysisIndependent statistical analysis of BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00326495).
- BCC-RAD-13Independent statistical analysis of Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- BE ACTIVE 2Independent statistical analysis of A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- BE HEARD IIIndependent statistical analysis of A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa: primary endpoint results, effect estimate with confidence interval, sample-size…
- BE READYIndependent statistical analysis of A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic…
- BE VIVIDIndependent statistical analysis of A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis: primary…
- BEACONIndependent statistical analysis of HDR Brachytherapy, EBRT and STAD for the Treatment of Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- BEACON IIIndependent statistical analysis of Evaluation of Methods for Implementation of a Comfort Care Order Set: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- BEAGLE R21Independent statistical analysis of Behavioral Economics Applications to Geriatrics Leveraging EHRs: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03704389).
- BEAMIndependent statistical analysis of A Study to Evaluate the Effectiveness of Juvéderm® VOLIFT®™ With Lidocaine for Dynamic Radial Cheek Line Skin Depressions: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- BEe-HIVeIndependent statistical analysis of B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- BEGINIndependent statistical analysis of A Study of the Safety, Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint Disease: primary endpoint results, effect estimate with confidence interval,…
- BEGSIndependent statistical analysis of Benralizumab for Eosinophilic Gastritis (BEGS): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03473977).
- Behavior During Experimentally Induced Pain: Complete Statistical AnalysisIndependent statistical analysis of Behavior During Experimentally Induced Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01594528).
- Behavioral Activation Intervention for Smoking Cessation in Smokers With Depressive Symptoms: Complete Statistical AnalysisIndependent statistical analysis of Behavioral Activation Intervention for Smoking Cessation in Smokers With Depressive Symptoms: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Behavioral Activation Intervention, Reward Processing, and Youth Smoking Cessation: Complete Statistical AnalysisIndependent statistical analysis of Behavioral Activation Intervention, Reward Processing, and Youth Smoking Cessation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01351766).
- Behavioral Economic Treatment to Enhance Rural (BETTER) Living: Complete Statistical AnalysisIndependent statistical analysis of Behavioral Economic Treatment to Enhance Rural (BETTER) Living: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05235971).
- Behavioral Economics and Communication: Complete Statistical AnalysisIndependent statistical analysis of Behavioral Economics and Communication: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05918393).
- Beige Fat, Energy, and the Natriuretic Peptide System: Complete Statistical AnalysisIndependent statistical analysis of Beige Fat, Energy, and the Natriuretic Peptide System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04357964).
- BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115: Complete Statistical AnalysisIndependent statistical analysis of BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115: primary endpoint…
- Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04676360).
- Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients: Complete Statistical AnalysisIndependent statistical analysis of Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02152345).
- Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin: Complete Statistical AnalysisIndependent statistical analysis of Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin:…
- Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin’s Lymphoma(NHL): Complete Statistical AnalysisIndependent statistical analysis of Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00426855).
- Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00705250).
- Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL): Complete Statistical AnalysisIndependent statistical analysis of Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- BENEFITIndependent statistical analysis of Crossover Comparison of MultiHance and Dotarem: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02070380).
- Benefit of Assistive Listening Device for Lateralization: Complete Statistical AnalysisIndependent statistical analysis of Benefit of Assistive Listening Device for Lateralization: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05072457).